Title :

Evaluation of a rapid semiquantitative lateral flow assay for the prediction of serum neutralizing activity against SARS-CoV-2 variants.

Author(s) :

Hirabidian, Mickael [Auteur]
Laboratoire de Virologie - ULR 3610 [Laboratoire de Virologie]
Bocket, Laurence [Auteur]
Laboratoire de Virologie - ULR 3610 [Laboratoire de Virologie]
Demaret, Julie [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Vuotto, Fanny [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Rabat, Anthony [Auteur]
Laboratoire de Virologie - ULR 3610 [Laboratoire de Virologie]
Faure, Karine [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Labalette, Myriam [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Hober, Didier [Auteur]
Laboratoire de Virologie - ULR 3610 [Laboratoire de Virologie]
Lefevre, Guillaume [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Alidjinou, Enagnon Kazali [Auteur]
Laboratoire de Virologie - ULR 3610 [Laboratoire de Virologie]

Journal title :

Journal of Clinical Virology

Pages :

105268

Publisher :

Elsevier

Publication date :

2022-08-24

ISSN :

1386-6532

English keyword(s) :

SARS-CoV-2
Neutralizing antibodies
Variants
Lateral flow assay

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

BackgroundNeutralizing antibodies (NAbs) against SARS-CoV-2 have been shown to correlate with protection against infection. Simple tools such as lateral flow assays (LFA) that can accurately measure NAbs may be useful for ...
Show more >BackgroundNeutralizing antibodies (NAbs) against SARS-CoV-2 have been shown to correlate with protection against infection. Simple tools such as lateral flow assays (LFA) that can accurately measure NAbs may be useful for monitoring anti-SARS-CoV-2 immunity in the future.ObjectivesWe assessed the performance of the ichroma™ COVID-19 nAb test, a rapid semiquantitative LFA, for the prediction of serum neutralizing activity against SARS-CoV-2 variants.Study designSerum samples were collected from COVID-19 recovered patients and vaccinated individuals. The result of the ichroma assay was provided as inhibition rate, and was compared to anti-SARS-CoV-2 IgG levels, and NAbs against Alpha, Delta and Omicron variants.ResultsA total of 90 sera from recovered unvaccinated patients and 209 sera from the vaccine cohort were included in this study. In post-infection samples, the ichroma inhbition rate was found to be correlated with IgG levels (ρ = 0.83), and with anti-Alpha NAbs levels (ρ = 0.78). In the vaccine cohort, a good correlation was also observed between the ichroma inhibition rate and IgG levels (ρ = 0.84), as well as NAbs against Alpha (ρ = 0.62), Delta (ρ = 0.88) and Omicron (ρ = 0.74). An ichroma inhbition rate of 77.2%, 90.8% and 99.6% accurately predicted neutralization against Alpha, Delta and Omicron variants respectively.ConclusionsThe ichroma™ COVID-19 nAb assay, with appropriate variant cut-offs, can be useful for the monitoring of anti-SARS-CoV-2 immunization and may provide a rapid prediction of protection, especially in individuals with significant levels of NAbs.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

ANR Project :

ULNE

Collections :

• Centre d'Infection et d'Immunité de Lille (CIIL) - U1019 - UMR 9017

Source :

Harvested from HAL